Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data
(7h)
Evommune’s Dupixent-like phase 2 eczema data drive 75% stock rally
(8h)
AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
(8h)
BioPharma Dive
Novo combination obesity shot meets goal in diabetes trial
(1w)
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
(1w)
GSK walks away from pioneering Wave RNA editing drug
(1w)
Endpoints News
Isomorphic claims major advance with new AI drug design engine
(2h)
ILiAD raises $115M round to advance whooping cough vaccine
(2h)
AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight
(2h)
BioSpace
Webinar: 2026 Hiring Trends and Job Market Signals
(1h)
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
(7h)
Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
(9h)
STAT News
We tested the government’s official new AI nutrition tool: Grok
(1h)
Landmark settlement could create new protections for harm reduction under disability law
(3h)
Abridge CTO on Epic and what’s after AI scribing
(3h)
BioPharma Trend
Isomorphic Labs Presents an AI Drug Design Engine That Goes Beyond AlphaFold 3
(2h)
Takeda Signs $1.7B AI-Enabled Small Molecule Discovery Deal with Iambic
(1d)
Flagship’s Generate Biomedicines Eyes IPO Amid Reopening Biotech Market Window
(5d)
Drug Channels
Copay Accumulators and Maximizers in 2025: Popular, Profitable, and Problematic
(12h)
In an Uncertain 340B Environment, Kalderos Offers a Clear Path Forward
(4d)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel
(6d)
European Biotechnology Magazine
This Memo sticks: CSL bites in Switzerland for antibody collaboration
(6h)
This Memo sticks: CSL bites in Switzerland for antibody collaboration
(7h)
4Moving Biotech raises €12m to prove whether GLP-1 can crack osteoarthritis
(8h)
Drug Hunter
vimseltinib
(6h)
The New WIZ-kid in Protein Degradation
(1d)
Module 1 Quiz
(1d)
Labiotech.EU
Astellas’ “strategic brands” and “primary focuses” after XTANDI
(9h)
Breast cancer treatments heat up: Six therapies poised to transform patient outcomes
(1d)
Top biotech deals in January 2026
(4d)
Bio IT World
Trends from the Trenches: What Lies Ahead in Bioinvestment
(17h)
The Role of the Statistical Programmer is Evolving: Here’s How It’s Changing and What That Means for Pharmaceutical Companies
(4d)
PacBio Sells Their Short-Read IP to Illumina
(1w)
GEN News
ALS and Dementia Linked to Bacterial Sugar via Gut–Brain Axis
(1h)
How Long COVID-Related Brain Changes May Link to Alzheimer’s Disease
(2h)
Gator Bio and Hudson Lab Display Antibody Discovery Automation Solution at SLAS
(3h)
Cure Today
Keytruda Combo Approved for Platinum-Resistant Ovarian Cancer
(1h)
From Missed Signs to Second Chances After a Liver Cancer Diagnosis
(2h)
Chris Draft Shares Steps to Help Patients Regain Control After Cancer
(3h)
Contract Pharma
Waters Completes Combination With BD Biosciences, Diagnostic Solutions Businesses
(1d)
Bruker Introduces Label-Free Characterization Platform for Nanoscale Bioparticles
(1d)
Innovent and Lilly’s Seventh Collaboration Sets Model to Accelerate Pipeline Development
(1d)
Pharma Times
AstraZeneca bladder cancer therapy wins NICE backing
(12h)
Head masters
(12h)
Strong clinical data for Breye lead asset danegaptide
(1d)
Medcity News
Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis
(1h)
Lilly’s Chief Information & Digital Officer: AI Use Goes Far Beyond Just Drug Discovery
(2h)
Solace Health Reaches Unicorn Status by Taking the ‘Homework’ Out of Care Navigation
(3h)
Chemical & Engineering News
EPA reapproves dicamba use, despite MAHA opposition and previous court bans
(4h)
Feb. 10 Business Watch: Biotech IPOs are back; FMC may soon be for sale
(4h)
Obituary: Lal Vishwakarma
(8h)
The Pharma Letter
Kailera and Hengrui report ribupatide delivers 12.1% weight loss at 26 weeks
(5h)
Novo Nordisk commences legal action against Hims & Hers
(5h)
AstraZeneca’s Imfinzi wins NICE nod as first perioperative IO treatment for MIBC
(6h)
Targeted Oncology
Analysis Reveals Survival Gap, Racial Disparities in Ovarian Cancer Research
(5d)
Addressing the Overlooked: A New Approach to Treatment-Related High-Risk MDS
(5d)
Balancing Efficacy and Toxicity of Oral SERDs in Breast Cancer
(6d)
MedWatch
Former FDA chief backs Novo Nordic against Hims & Hers: They've crossed the line
(8h)
AstraZeneca expects robust 2026, led by strong cancer drug demand
(10h)
BII expands beyond Denmark: Launches units in UK and Italy
(11h)
In The Pipeline
Gumming Things Up On Purpose
(1h)
Crystals Where There Were None
(5d)
What the Literature is Filling Up With
(6d)
Pharmaphorum
FDA kicks off review of Takeda's narcolepsy hopeful
(6h)
Kailera stakes a claim to the oral weight loss category
(8h)
Kailera, Hengrui stake claim to oral weight loss category
(8h)
Drug Discovery Weekly
Charles River and Synthace to advance assay development
(6h)
Emulate showcases organ-chip platform at SLAS2026
(6h)
SLAS2026: Day One Round-Up
(9h)
HIT Consultant
Solace Health Raises $130M to Expand Patient Advocacy Network
(1h)
Garner Health Secures $118M to Reward Top Doctors
(1h)
Midstream Health Partners with CommonSpirit Health to Deploy AI Financial Operations Platform
(8h)
Insights: Pink Sheet
Sobi Takes Second Shot At EU Gamifant Approval
(2h)
Potential Blockbusters From AstraZeneca And Lilly Now Under EMA Review
(2h)
GLP-1s Likely TrumpRx Savings Focus Over Old, Genericized Products
(4h)
BioXconomy
Experts unveil AI breakthroughs in streamlining regulatory reviews
(5h)
Capsida confirms cause of death in clinical trial fatality for rare genetic disorder
(9h)
Lilly to buy Orna in CAR T deal worth up to $2.4bn
(10h)
BioCentury
Start-up funding, the perils of compounding, and neuropsych insights — a BioCentury podcast
(21h)
Galux: Scaling AI-designed biologics
(22h)
The next wave of biotech growth — a Perspective
(1d)
SCRIP
Evommune’s Atopic Dermatitis Data Competitive With Dupixent
(34m)
CSL CEO Paul McKenzie Exits With Former Exec Gordon Naylor Stepping In
(4h)
FDA Delivers Regenxbio Another Blow, This Time for RGX-121
(4h)